Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
The UK government will subject leading video-on-demand platforms, including Netflix and Amazon Prime Video, to stronger regulation enforced by Ofcom under secondary legislation implementing the Media Act 2024. Services with more than 500,000 UK users will enter a new Tier 1 category and must comply with a VoD standards code modelled on the Broadcas…
Williams Trading has reiterated a Buy rating and a $39.00 price target on Genesco Inc., arguing that the stock’s retreat since January 20, 2026 creates a buying opportunity. The target implies roughly 48% upside from the current share price of $26.38. The firm trimmed near-term revenue and earnings forecasts to reflect store rationalization and a f…
Stifel raised its 12-month price objective on BioMarin Pharmaceutical Inc. to $68 from $61 while retaining a Hold recommendation. The firm highlighted the strategic and financial merits of the Fold Therapeutics transaction even as fourth-quarter 2025 results showed an EPS shortfall and revenue slightly above expectations. Key questions remain aroun…
China's nine-day Lunar New Year holiday produced a strong rebound in domestic travel and consumer spending, with official data showing 596 million domestic trips and 803.5 billion yuan in tourism receipts. Gains were widespread across major cities, scenic areas and lower-tier destinations, while the box office recorded a sharp decline in takings an…
China equities have faced downward pressure so far this year led by internet and auto stocks, driven by earnings revisions in e-commerce and cooling sentiment toward AI hyperscalers. At the same time, market breadth has improved: more than 60% of MSCI China constituents are outperforming the index, with industrials, commodities and pharma/biotech a…
Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock decline about 20% on Tuesday after the company released 12-week results from the 20 mg cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease. Data from 12 evaluable patients showed a mean absolute fetal hemoglobin gain of 12.2 percentage points and improvements in markers of …
H.C. Wainwright revised its price target for Integra Resources Corp. to $7.00 from $7.25 while keeping a Buy rating, a move the firm says reflects dilution from a recent equity raise priced below the company's net asset value per share. Integra released a three-year operating plan for its Florida Canyon mine that forecasts near-term production of 7…
<p>American Shared Hospital Services (AMS) looks mispriced. Recent headlines around automation and AI replacing clinical services have pushed sentiment lower for capital-intensive, people-driven treatment providers. That worry is misplaced for a company that leases Gamma Knife and other radiosurgery equipment, reported 17% revenue growth in Q1 2025…
H.C. Wainwright reduced its 12-month price target on Armata Pharmaceuticals (ARMP) to $15 from $19 while maintaining a Buy rating. The new target implies roughly 57% upside from the current share price of $9.54. The broker highlighted the Qualified Infectious Disease Product (QIDP) designation for AP-SA02 and the regulatory benefits that designatio…
Futures tied to Canada’s primary equity gauge inched lower on Tuesday as investors weighed a cluster of cross-cutting risks: worries about the impact of powerful artificial intelligence models, unresolved questions over new U.S. global tariffs, and upcoming Canadian bank earnings that may reflect slower loan growth. Moves in materials stocks and co…
Major technology and infrastructure companies have struck a series of multi-billion-dollar contracts to secure artificial intelligence compute, chips and data-center capacity. Agreements span leading chipmakers, cloud providers, data-center operators and AI startups, with some arrangements including equity options, licensing of intellectual propert…
A widely circulated hypothetical report outlining a grim 2028 unemployment outcome tied to rapid AI-driven layoffs has unsettled markets already heavily exposed to the technology. Investors have moved out of software equities and into defensive names and parts of the AI supply chain perceived as durable winners, prompting sharp sectoral divergence …
Needham increased its target price for Ultra Clean Holdings to $70 from $50 while retaining a Buy rating, citing management commentary and upgraded guidance that pushed first-quarter 2026 revenue above expectations. The shares have rallied strongly year-to-date but an independent valuation flagged the stock as overvalued relative to its Fair Value …
H.C. Wainwright raised its price target on Bausch + Lomb (BLCO) to $20 from $17 while reaffirming a Buy rating. The firm pointed to a fourth-quarter revenue beat and company guidance implying 5% to 7% constant currency top-line growth for 2026. Bausch + Lomb posted revenue growth across Vision Care, Surgical and Pharmaceuticals in the fourth quarte…
AES Corporation shares climbed 2% following the announcement of multi-decade energy supply and management agreements with Google for a new data center in Wilbarger County, Texas. The arrangement includes 20-year Power Purchase Agreements, AES ownership and operation of generation assets, and a long-term energy management contract to provide powered…
Director Hunt James Christopher acquired 10,000 shares of Kelly Services Inc (NASDAQ:KELYA) on February 20, 2026, paying an average of $9.5733 per share for a total of $95,733. The transaction increases his direct holdings to 15,976 shares as the company navigates a pending sale of a controlling interest and has implemented a stockholder rights pla…
UBS downgraded Belgian transmission operator Elia from "buy" to "neutral" while lifting its 12-month price target to €144 from €117, arguing that the stock's recent advance has already captured expected improvements in allowed returns across Germany and Belgium. The broker raised earnings and EBITDA forecasts on a higher assumed return on equity bu…
Leerink Partners raised its price target on XOMA, Ltd. (NASDAQ:XOMA) to $50 from $45 while keeping an Outperform rating, citing updated royalty expectations and a lower discount rate in its DCF model. The firm cut certain pipeline assumptions after a Phase 3 failure and incorporated dilution from convertible preferred shares, producing lower 2030 r…
Leerink Partners trimmed its price target for Hims and Hers Health to $17.50 from $20.00 while keeping a Market Perform rating, citing difficulty reconciling a broader product slate with continuing concerns about the company’s weight-loss business. The stock trades near its 52-week low, and analysts point to margin pressures, regulatory and legal u…
Goldman Sachs cut its price target on ACV Auctions to $10 from $13 but left the stock at a Buy after the company's fourth-quarter 2025 results. ACV delivered revenue above expectations but missed on EPS; management outlined growth investments and provided guidance for modest revenue expansion in 2026. Other broker commentary and third-party analysi…
Advanced Micro Devices saw its stock climb 14% on Tuesday morning after unveiling an expanded multi-year, multi-generation deal with Meta to deploy as much as 6 gigawatts of AMD Instinct GPUs for AI infrastructure. The agreement includes a staged shipment schedule beginning in the second half of 2026, a performance-linked warrant for up to 160 mill…
Bank of America Securities analysts say Brazil, Canada and Mexico look positioned to be relative beneficiaries of U.S. President Donald Trump’s newly implemented global tariffs. The levies, issued under Section 122 of the 1974 Trade Act, began at 10% following a Supreme Court decision that limited the administration’s prior reciprocal tariff author…
Palvella Therapeutics shares climbed 15% after the company reported positive topline results from its Phase 3 SELVA trial of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations. The study met its primary endpoint and a pre-specified key secondary endpoint with strong statistical significance, showed favorable tolerability an…
BofA Securities launched coverage of PicPay (PICS) with a buy rating and a $27.00 price target, citing the companys pivot into credit underwriting as the primary driver of future earnings. The firm forecasts a 117% EPS compound annual growth rate through 2028 and expects return on equity to rise above 30% from a current trailing-12-month ROE of 16…
Raymond James moved Vir Biotechnology (VIR) from Outperform to Strong Buy and increased its price objective to $19 from $12 after the company released Phase 1 data for VIR-5500 and announced a development deal with Astellas. Vir also posted fourth-quarter and full-year 2025 results that beat expectations for both EPS and revenue. The stock trades a…
